BNET Industries
Last Fiscal Year Sales:$864.9M
- Private
- UK
Dow Jones Description
Provider of Logistics & Supply Chain Management Services to Oil & Gas Exploration & Production Companies
CEO
Billy AllanNumber of Employees 1,620
Peer Companies
NAICS Code Administrative Management and General Management Consulting Services: 541611
News & Analysis
Filter by
asco plc. and methylgene inc. - All News and Analysis
MethylGene Reports Clinical Data for MGCD0103 at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting
- 2008-06-02
MethylGene Inc. (TSX: MYG) today announced preliminary data from two ongoing clinical studies with MGCD0103, a novel, isoform-selective histone deacetylase HDAC inhibitor, conducted in collaboration with Celgene Corporation and Taiho Pharmaceutical. Results from a Phase II study evaluating MGCD0103 as a single-agent in Hodgkin lymphoma HL (Trial 010) were reported...
MethylGene and Pharmion Report Preliminary Data for MGCD0103 at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting.
- 2007-06-02
CHICAGO, ILLINOIS, Jun 2, 2007 CCNMatthews via COMTEX -- HDAC Inhibitor MGCD0103 Demonstrates Substantial Response Rate in Two Clinical Trials 40% Response Rate and 45% Disease Control Rate in Single-Agent Phase II Trial in Refractory or Relapsed Hodgkin's Lymphoma Patients ...
Clinical Data From MethylGene's HDAC Compound MGCD0103 to be Presented at the 2007 American Society of Clinical Oncology Annual Meeting
- 2007-05-22
MethylGene Inc. (TSX: MYG), along with its collaborator Pharmion Corporation (NASDAQ: PHRM), today announced the presentation of three abstracts, one which is an oral presentation for MGCD0103, an oral isotype-selective histone deacetylase HDAC inhibitor, at the 2007 American Society of Clinical Oncology ASCO Annual Meeting held in Chicago from June...
Clinical Data From MethylGene's HDAC Compound MGCD0103 to be Presented at the 2007 American Society of Clinical Oncology Annual Meeting; Two posters and one oral presentation for MGCD0103.
- 2007-05-22
MONTREAL, QUEBEC, May 22, 2007 CCNMatthews via COMTEX -- MethylGene Inc. (TSX:MYG), along with its collaborator Pharmion Corporation (NASDAQ:PHRM), today announced the presentation of three abstracts, one which is an oral presentation for MGCD0103, an oral isotype-selective histone deacetylase HDAC inhibitor, at the 2007 American...
MethylGene Reports Positive Interim Results from Two Clinical Programs at the American Society of Clinical Oncology Conference, ASCO
- 2006-06-05
Interim Data From HDAC Inhibitor, MGCD0103, Includes Three Leukemia Patients Exhibiting Complete Bone Marrow Responses MethylGene Inc. (TSX: MYG) today announced interim data for its lead oncology product candidate, MGCD0103, an oral, non-hydroxamate, isotype-selective histone deacetylase HDAC inhibitor at the American Society of Clinical Oncology ASCO 2006 Annual Meeting...
MethylGene Reports Positive Interim Results from Two Clinical Programs at the American Society of Clinical Oncology Conference, ASCO.
- 2006-06-05
MONTREAL, QUEBEC, Jun 5, 2006 CCNMatthews via COMTEX -- Interim Data From HDAC Inhibitor, MGCD0103, Includes Three Leukemia Patients Exhibiting Complete Bone Marrow Responses MethylGene Inc. (TSX:MYG) today announced interim data for its lead oncology product candidate, MGCD0103, an oral, non-hydroxamate, isotype-selective histone...
MethylGene Discloses Preliminary MGCD0103 'an Oral HDAC Inhibitor' Phase I Clinical Data at ASCO-Interim Results Reported for Ongoing Clinical Trials
- 2005-05-16
MONTREAL -- MethylGene Inc. (TSX:MYG), a biopharmaceutical company focused on cancer and infectious disease, today announced preliminary Phase I clinical data for its oncology product candidate, MGCD0103, an oral, non-hydroxamate, isotypic selective histone deacetylase HDAC inhibitor.The preliminary results demonstrated the safety, tolerability, pharmacokinetic and pharmacodynamic properties of...
MethylGene Discloses Preliminary MG98 Clinical and Preclinical Data at ASCO-Interim Results Reported for Ongoing Clinical Trials
- 2005-05-16
MONTREAL -- MethylGene Inc. (TSX:MYG), a biopharmaceutical company focused on cancer and infectious disease, today announced preliminary clinical and preclinical data for its oncology product candidate MG98, a DNA methyltransferase mRNA inhibitor. Results for three studies were disclosed: MG98/Interferon Phase II Step 1 renal cell carcinoma...
MethylGene Discloses Preliminary MGCD0103 'an Oral HDAC Inhibitor' Phase I Clinical Data at ASCO-Interim Results Reported for Ongoing Clinical Trials-.
- 2005-05-16
MONTREAL, QUEBEC, May 16, 2005 CCNMatthews via COMTEX MethylGene Inc. (TSX:MYG), a biopharmaceutical company focused on cancer and infectious disease, today announced preliminary Phase I clinical data for its oncology product candidate, MGCD0103, an oral, non-hydroxamate, isotypic selective histone deacetylase HDAC inhibitor. The...
MethylGene Discloses Preliminary MG98 Clinical and Preclinical Data at ASCO-Interim Results Reported for Ongoing Clinical Trials.
- 2005-05-16
MONTREAL, QUEBEC, May 16, 2005 CCNMatthews via COMTEX MethylGene Inc. (TSX:MYG), a biopharmaceutical company focused on cancer and infectious disease, today announced preliminary clinical and preclinical data for its oncology product candidate MG98, a DNA methyltransferase mRNA inhibitor. Results for three studies were ...
- 1
- 2
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Billy Allan | CEO |
| Bill Loch | Director, Strategic Dev |
| Derek Smith | Director, Operations |
| Ian Ross | Director, Finance |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Mike Salter | Chairman |
| Hugh Lenon | Board of Directors |
| Jim Cooper | Board of Directors |
| Richard Daw | Board of Directors |
| Rodney Lenthall | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Asco plc | Director, Strategic Dev | Current |
| Asco plc | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Asco plc | Director, Operations | Current |
| Asco plc | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Asco plc | Chairman | Current |
| Organization | Position | Status |
|---|---|---|
| Asco plc | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Asco plc | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Asco plc | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Asco plc | Board of Directors | Current |
Industry Transcripts by Seeking Alpha
-
51jobs Q3 2009 Earnings Call Transcript
on Nov 23, 2009about JOBS
-
NetEase Q3 2009 Earnings Call Transcript
on Nov 18, 2009about NTES
-
Franklin Covey Co. F4Q09 (Qtr End 08/31/09) Earnings Call Transcript
on Nov 16, 2009about FC
-
Cellcom Israel Ltd. Q3 2009 Earnings Call Transcript
on Nov 16, 2009about CEL
-
URS Corporation Q3 2009 Earnings Call Transcript
on Nov 13, 2009about URS
Glass Door
ASCO (United Kingdom)
IndustryTop Rated
